Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is a leader in the medical device industry, particularly in advanced stages of structural heart disease. With strong sales growth and a well-rounded portfolio across multiple product lines, including surgical tissue heart valves and transcatheter aortic valves, the company has shown resilience in its core business and potential for future expansion. Its strong financial outlook, innovative product pipeline, and potential for market share gains make it a promising investment opportunity in the medical device sector.

Bears say

Edwards Lifesciences is set to maintain its strong position in the TAVR market, with a projected growth rate of 7%-9% y/y, but downside risks such as potential market saturation and increased competition pose a threat to its ability to sustain growth. Additionally, the company's efforts to expand into the mitral and tricuspid valve markets may face challenges and delays in gaining market traction, which could impact its overall revenue and profitability. These potential risks lead to a negative outlook on the stock.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.